# AstraZeneca Plc reports revenue up 10%, strong pipeline progress

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-reports-revenue-up-10-strong-pipeline-progress/4121194397
- Published: 2025-04-29T07:58:51+01:00
- Author: Amilia Stone

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced its Q1 2025 results.

_Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards
2030 ambition_

**Revenue and EPS summary**

|  | Q1 2025 |         % Change | 
|  | $m  | Actual  | CER^(1) | 
| _  – Product Sales_ | 12,875 | 6 | 9 | 
| _  – Alliance Revenue_ | 639 | 40 | 42 | 
| Product Revenue^(2) | 13,514 | 7 | 10 | 
| Collaboration Revenue | 74 | 64 | 64 | 
| **Total Revenue** | **13,588** | **7** | **10** | 
| **Reported EPS ($)** | **1.88** | **34** | **32** | 
| **Core**^(3) **EPS ($)** | **2.49** | **21** | **21** |

Key performance elements for Q1 2025

(Growth numbers at constant exchange rates)

*   Total Revenue up 10% to $13,588m, driven by double-digit growth in Oncology 
and BioPharmaceuticals

*   Growth in Total Revenue across all major geographic regions

*   Core Operating profit increased 12%

*   Core Tax rate of 16% in the quarter due to timing of settlements. Expectations
for the full year Core tax rate are unchanged at 18-22%

*   Core EPS increased 21% to $2.49

*   Five positive Phase III readouts and 13 approvals in major regions since the
prior results

> **Pascal Soriot, Chief Executive Officer, AstraZeneca, said:**
> “Our strong growth momentum has continued into 2025 and we have now entered an
> unprecedented catalyst-rich period for our company.
> Already this year we have announced five positive Phase III study readouts, including
> most recently the highly anticipated DESTINY-Breast09 for Enhertu, as well as 
> SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these 
> will feature in the ASCO 2025 plenary sessions, reflecting the significance of
> these data to the oncology community.
> Our company is firmly committed to investing and growing in the US and we continue
> to benefit from our broad-based source of revenue and global manufacturing footprint,
> including eleven production sites in the US covering small molecules, biologics
> as well as cell therapy. Additionally, we have even greater US investment in manufacturing
> and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge
> MA.
> Overall, we are making excellent progress toward our ambition of eighty billion
> dollars in Total Revenue by 2030.”

See Table 1 for details of clinical trial results since the prior earnings announcement,
including DESTINY-Breast09, MATTERHORN, and  SERENA-6.

See Note 4 for the locations of the eleven US manufacturing sites.

**Guidance**

AstraZeneca reiterates its Total Revenue and Core EPS guidance^(5) for FY 2025 at
CER, based on the average foreign exchange rates through 2024.

**Total Revenue** is expected to increase by a **high single-digit** percentage

**Core EPS** is expected to increase by a **low double-digit** percentage

–  The Core Tax rate is expected to be between 18-22%

–  If foreign exchange rates for April 2025 to December 2025 were to remain at the
average rates seen in March 2025, it is anticipated that compared to the performance
at CER, FY 2025 Total Revenue would incur a low single-digit percentage adverse 
impact (unchanged from prior guidance), and Core EPS would incur a low single-digit
percentage adverse impact (previously mid single-digit).

[5152G_1-2025-4-28](https://www.directorstalkinterviews.com/wp-content/uploads/2025/04/5152G_1-2025-4-28.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2025/04/5152G_1-2025-4-28.pdf)

Share on:
